OncoDNA:  Selected to be NBCC’s (Riyadh, Saudia Arabia) preferred supplier of clinical grade molecular diagnostics for cancer

OncoDNA SA expands its territory with the recent announcement of a supplier agreement with NBCC (National Blood and Cancer Center); a specialized centre for diagnosing and treating blood diseases and cancers located in Riyadh, Saudi Arabia, with the intent to bring affordable and state-of-the-art DNA sequencing technologies to the GCC countries so as to help oncologists make the best decisions regarding treatment choice.

In keeping in line with this goal of providing innovative high-quality technologies at a low-cost to Saudi Arabia and its neighboring countries, NBCC has chosen OncoDNA as its preferred supplier of clinical grade molecular diagnostics using the OncoDEEP DX and Clinical cancer panels. Ultimately, the collaboration agreement with OncoDNA will enable GCC physicians to access medical innovations based on next gen sequencing, providing them with clinically relevant interpretations of patients’ tumours.

Mr. Jean-Pol Detiffe, founder and CEO of OncoDNA, said: “With this supplier agreement, OncoDNA is continuing to fulfill its ambitions, using innovations based on the targeted or complete sequencing of tumour genomes to help medical doctors make the right treatment choice and better monitor tumour development in the patient. More interestingly, we have shown that our OncoDEEP solution can be exported all over the world.”

More on this story

Read previous OncoDNA posts

Source:

www.oncodna.com

Contact:

OncoDNA SA
Jean-Pol Detiffe
Founder & Chief Executive Officer
25 Avenue Georges Lemaître
6041 Gosselies, Belgium
Tel. +32 71 347899
E-mail: jp.detiffe@oncodna.com
www.oncodna.com

National Blood and Cancer Center
Dr. Ali S. AlShanqeeti
Chief Executive Officer
King Abdullah Road
Riyadh, Kingdom of Saudi Arabia
Tel. +966 11 2881144
FAX.+966 11 2881155
E-mail: ashanqeeti@bloodandcancer.org
www.bloodandcancer.org

 

Related Articles

Share

About Author

Win-health

(0) Readers Comments

Comments are closed.